• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Edesa Biotech Inc.

    6/18/26 5:05:37 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EDSA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Edesa Biotech, Inc.

    (Name of Issuer)


    Common Shares, without par value

    (Title of Class of Securities)




    27966L306

    (CUSIP Number)
    06/11/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    27966L306


    1Names of Reporting Persons

    Integrated Core Strategies (US) LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    520,685.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    520,685.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    520,685.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    27966L306


    1Names of Reporting Persons

    Millennium Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    520,685.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    520,685.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    520,685.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    27966L306


    1Names of Reporting Persons

    Millennium Group Management LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    520,685.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    520,685.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    520,685.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    27966L306


    1Names of Reporting Persons

    Israel A. Englander
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    520,685.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    520,685.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    520,685.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Edesa Biotech, Inc.
    (b)Address of issuer's principal executive offices:

    100 Spy Court, Markham, Ontario, Canada L3R 5H6
    Item 2. 
    (a)Name of person filing:

    Integrated Core Strategies (US) LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander
    (b)Address or principal business office or, if none, residence:

    Integrated Core Strategies (US) LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
    (c)Citizenship:

    Integrated Core Strategies (US) LLC - Delaware Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
    (d)Title of class of securities:

    Common Shares, without par value
    (e)CUSIP Number(s):

    27966L306
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See response to Item 9 on each cover page.
    (b)Percent of class:

    See response to Item 11 on each cover page. The percent of class was calculated based on 9,621,192 Common Shares outstanding, which is the sum of (i) 8,891,951 Common Shares outstanding as of May 13, 2026, as reported in the issuer's Form 10-Q filed with the SEC on May 14, 2026, and (ii) 729,241 Common Shares issued in connection with a private placement that closed on or about June 15, 2026, as reported in the issuer's Form 8-K filed with the SEC on June 11, 2026.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See response to Item 5 on each cover page.

     (ii) Shared power to vote or to direct the vote:

    See response to Item 6 on each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See response to Item 7 on each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    See Exhibit I
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Integrated Core Strategies (US) LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/17/2026
     
    Millennium Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/17/2026
     
    Millennium Group Management LLC
     
    Signature:/s/ Gil Raviv
    Name/Title:Gil Raviv, Global General Counsel
    Date:06/17/2026
     
    Israel A. Englander
     
    Signature:/s/ Israel A. Englander
    Name/Title:Israel A. Englander
    Date:06/17/2026

    Comments accompanying signature:  ** INTEGRATED CORE STRATEGIES (US) LLC By: Integrated Holding Group LP, its Managing Member By: Millennium Management LLC, its General Partner
    Exhibit Information

    Exhibit I: Joint Filing Agreement, dated as of June 17, 2026, by and among Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

    Get the next $EDSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDSA

    DatePrice TargetRatingAnalyst
    12/20/2021$16.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors

    TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity ("PIPE") financing that is expected to result in gross proceeds of approximately $3.5 million to the Company, before deducting offering expenses payable by Edesa. The common shares were placed without an agent, underwriter, broker or dealer. Investors in the PIPE include Edesa's Chief Executive Officer and healthcare-focused investors. The PIPE is ex

    6/11/26 9:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury

    Analyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today at the 63rd European Renal Association Congress TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury (AKI) and respiratory distress. The data, which expand upon previously reported Phase 3

    6/5/26 9:20:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

    Oral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it will present data on paridiprubart, its first-in-class anti-TLR4 antibody, at the 63rd European Renal Association (ERA) Congress, to be held June 3 – 6, 2026, in Glasgow, Scotland. The ERA Congress is one of the world's leading nephrology meetings, convening clinicians and researchers focused on kidney disease. Edesa's accepted oral presentation will feature

    5/19/26 9:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Edesa Biotech Inc.

    SCHEDULE 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    6/18/26 5:05:37 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Edesa Biotech, Inc. (0001540159) (Filer)

    6/11/26 9:20:32 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Inc. filed SEC Form 8-K: Other Events

    8-K - Edesa Biotech, Inc. (0001540159) (Filer)

    6/5/26 9:25:18 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep bought $6,599 worth of shares (1,000 units at $6.60), increasing direct ownership by 0.16% to 628,813 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/10/26 5:02:16 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $39,000 worth of shares (10,000 units at $3.90) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/6/26 5:01:15 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep bought $42,560 worth of shares (10,000 units at $4.26) (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    3/5/26 5:01:11 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Nijhawan Pardeep was granted 153,550 shares, increasing direct ownership by 21% to 884,684 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    6/16/26 5:03:05 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Nijhawan Pardeep was granted 1,671 shares, increasing direct ownership by 0.23% to 731,134 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    6/1/26 5:00:12 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Marshall Patrick was granted 19,000 shares, increasing direct ownership by 36% to 71,666 units (SEC Form 4)

    4 - Edesa Biotech, Inc. (0001540159) (Issuer)

    5/29/26 5:02:29 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Edesa Biotech with a new price target

    HC Wainwright & Co. initiated coverage of Edesa Biotech with a rating of Buy and set a new price target of $16.00

    12/20/21 6:08:21 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Edesa Biotech Inc.

    SC 13D/A - Edesa Biotech, Inc. (0001540159) (Subject)

    11/1/24 8:50:52 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Edesa Biotech Inc.

    SC 13G - Edesa Biotech, Inc. (0001540159) (Subject)

    6/3/24 4:10:38 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Edesa Biotech Inc. (Amendment)

    SC 13G/A - Edesa Biotech, Inc. (0001540159) (Subject)

    1/29/24 4:29:02 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EDSA
    Leadership Updates

    Live Leadership Updates

    View All

    Edesa Biotech Announces Chief Financial Officer Transition

    TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in finance and corporate strategy within the biotechnology and pharmaceutical industries. Since August 2018, Mr. Weiler served as President of Exzell Pharma, Inc., a privately held, commercial-stage ph

    4/4/25 4:15:46 PM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

    TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He is a veteran of the healthcare and biopharmaceutical sectors, with more than 20 years of experience in financial planning and analysis, licensing and mergers & acquisitions."Stephen joins Edesa at an exciting time as we build on our regulatory and clinical achievements and set our sights on additional growth opportunities. He shares our disciplined, manage-like-owner

    6/27/23 8:15:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Edesa Biotech Appoints Strategy Expert to Board of Directors

    TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors."Ms. Chao's appointment to our Board comes at an exciting time as we prepare for the most meaningful milestones yet in our clinical programs. Her extensive experience in the life science sector and capital markets will be a valuable resource to Edesa and its shareholders," said Par Nijhawan, MD, Chief Executive Officer of Edesa.Ms. Chao has more than 25 years of experience in the biotech and life sciences industries focused primarily

    3/29/22 9:00:00 AM ET
    $EDSA
    Biotechnology: Pharmaceutical Preparations
    Health Care